Our Pipeline

A dose-ranging Phase 2 trial evaluating EDP1815 for the treatment of mild to moderate psoriasis. The trial is evaluating three doses of EDP1815 versus placebo in approximately 225 individuals, over a 16-week treatment period.

EDP1815 is entering a Phase 2 trial in atopic dermatitis in 3Q 2021.

Preclinical candidate is the next wave of SINTAX-based medicines, microbial extracellular vesicle (Es).

Preclinical candidate in the next wave of SINTAX-based medicines, microbial extracellular vesicles (EVs).

Chronic inflammation of the nervous system is believed to be a driver of neuro-inflammatory diseases (i.e. Multiple Sclerosis) and is also associated with neurodegenerative diseases (i.e. Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, etc.) Evelo is studying the impact of single strains of microbes on neuro-inflammation in preclinical studies. The most notable effect is the clearance of inflammatory cells in the spinal cord by these microbes. SINTAX is an effective portal to central inflammatory pathways without the need to cross the blood-brain barrier. This is potentially transformational in the treatment of neuroinflammatory and neurodegenerative diseases which have an inflammatory drive to their pathology.

Metabolic syndrome, which affects more than 30% of adults in the US, increases one’s risk of developing cardiovascular disease and type 2 diabetes. Metabolic syndrome is often accompanied by low grade chronic inflammation, which is has been implicated in both its development and progression of associated pathologies. Evelo is investigating the therapeutic potential of single strains of microbes on multiple aspects of metabolic syndrome (i.e., excess body fat, insulin resistance, triglyceride levels) in preclinical models.